Paris - Delayed Quote EUR

Nanobiotix S.A. (NANO.PA)

3.3650
+0.2550
+(8.20%)
At close: May 13 at 5:39:37 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for NANO.PA

Recent News: NANO.PA

View More
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
GlobeNewswire 2 days ago
Nanobiotix presents outcomes from trial of JNJ-1900 for pancreatic cancer

Nanobiotix presents outcomes from trial of JNJ-1900 for pancreatic cancer
Clinical Trials Arena 7 days ago
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
GlobeNewswire 9 days ago
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
GlobeNewswire 14 days ago
Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company
GlobeNewswire 29 days ago
Nanobiotix SA (NBTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Nanobiotix SA (NBTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
GuruFocus.com last month
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswire last month
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
GlobeNewswire last month
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
GlobeNewswire last month
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
GlobeNewswire last month
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
GlobeNewswire last month
View More

Related Tickers

ADOC.PA Adocia SA
4.8550
-1.02%
 
GNFT.PA Genfit S.A.
3.8420
-1.39%
 
IPH.PA Innate Pharma S.A.
1.9900
-1.00%
 
SIGHT.PA GenSight Biologics S.A.
0.2155
-0.46%
 
PHXM.PA PHAXIAM Therapeutics S.A.
0.3550
-1.39%
 
OSE.PA OSE Immunotherapeutics SA
6.09
+1.93%
 
ALCLS.PA Cellectis S.A.
1.3320
-1.33%
 
DBV.PA DBV Technologies S.A.
1.9440
+0.10%
 
ABVX.PA ABIVAX Société Anonyme
5.50
-2.48%
 
1TB0.SG Orphazyme AS
132.00
+5.60%